Cencora (COR) Q1 2026 earnings review
U.S. Strength and M&A Mask International Weakness
Cencora delivered a mixed but net-positive Q1. While consolidated revenue grew 5.5% and Adjusted EPS rose 9.4% to $4.08, the story is a tale of two segments. U.S. Healthcare Solutions is firing on all cylinders, driven by the RCA acquisition and strong specialty sales, delivering 21% operating income growth. Conversely, International Healthcare Solutions remains a drag, with operating income plunging nearly 14%. Management raised full-year Adjusted Operating Income guidance to 11.5%-13.5% growth, primarily to reflect the completed acquisition of OneOncology, validating their pivot toward high-margin provider services.
🐂 Bull Case
The pivot to high-margin specialty services is working. U.S. operating margins expanded significantly, driven by the integration of Retina Consultants of America (RCA) and strong specialty product sales. The acquisition of OneOncology further cements this moat.
Management raised FY26 Adjusted Operating Income guidance from 8-10% to 11.5-13.5%. While driven by M&A, it signals confidence in the ability of these new assets to accrete value immediately.
🐻 Bear Case
International Healthcare Solutions is in a sustained downtrend. Operating income fell 14% (17% constant currency) despite 9.6% revenue growth. This margin compression suggests structural issues in the European distribution and logistics businesses.
Net interest expense surged 159% YoY to $72.4M due to debt taken on for RCA. With $1.0B in annual CapEx and significant M&A outlays, the balance sheet is more levered, reducing flexibility for buybacks.
⚖️ Verdict: 🟢
Bullish. The strategic shift toward high-margin U.S. specialty services (RCA, OneOncology) is successfully offsetting legacy international weakness. The guidance raise confirms the thesis that Cencora is effectively trading low-margin distribution revenue for high-margin service profits.
Key Themes
OneOncology & RCA Driving U.S. Margins
The U.S. Healthcare Solutions segment grew Operating Income 21.0% YoY, massively outpacing its 5.0% revenue growth. This margin expansion (1.09% vs 0.95% GAAP) is directly attributable to the inclusion of Retina Consultants of America (RCA) and the impending contribution of OneOncology. These MSO (Management Services Organization) assets are fundamentally changing the margin profile of the domestic business.
International Profit Squeeze
International performance is Reversing. Despite a 9.6% revenue jump to $7.6B, operating income collapsed 13.9% (reported) and 17.0% (constant currency). Management cited lower operating income at the European distribution business. This disconnect between volume growth and profit decline indicates severe pricing pressure or cost inefficiencies in the European theater.
U.S. Consulting Services Impairment
A $249.5 million impairment charge was recorded related to the U.S. Consulting Services business, which is now classified as 'held for sale' in the Other segment. This indicates a failure to unlock value in this specific vertical and raises questions about the valuation of other peripheral services in the portfolio.
GLP-1 Volume Growth Persists
Revenue growth was supported by products labeled for diabetes and weight loss (GLP-1s). While lower margin, these products continue to drive massive unit volume through the U.S. channel, contributing to the 5.0% segment revenue lift.
Debt Service Costs Spiking
Interest expense, net, jumped to $72.4 million from $27.9 million a year ago (+159%). This is driven by senior notes and term loans issued to finance the RCA and OneOncology deals. While the debt is productive (buying EBITDA), it increases the hurdle rate for these acquisitions.
Other KPIs
Accelerating. Up 37 basis points YoY (from 3.11%). This is a significant move for a distributor, driven almost entirely by the mix shift toward higher-margin MSO assets (RCA) in the U.S. segment.
Stable/Seasonal. Cash usage is typical for Q1 due to inventory timing, but improved slightly from -$2.7 billion in the prior year Q1. Inventory levels rose to $24.1B from $20.5B at year-end, consuming working capital.
Accelerating. Adjusted operating expenses rose 21.7% YoY. This outpaced revenue growth (5.5%) significantly, reflecting the heavier cost structure of the newly acquired service businesses (RCA).
Guidance
Accelerating. Raised from prior guidance of 8%-10%. This revision is driven by the completion of the OneOncology acquisition and continued strength in the U.S. segment.
Stable. Range reaffirmed despite the operating income raise, likely due to higher interest expenses and share count assumptions holding steady (195.5M shares). Implies ~10% YoY growth at midpoint.
Accelerating. The prior implied run-rate was lower; this confirms that the U.S. segment is the sole engine of profit growth for the fiscal year.
Reversing. While the guidance calls for growth, the Q1 result (-17% constant currency) puts Cencora in a deep hole. Achieving this full-year target will require a massive turnaround in the remaining three quarters.
Key Questions
International Turnaround Viability
With International Operating Income down 17% in Q1 on a constant currency basis, what specific mechanisms give you confidence in reaffirming the 5-8% full-year growth target? Is this back-half weighted?
Consulting Business Divestiture
Regarding the $249.5M impairment in U.S. Consulting Services—is the 'held for sale' classification a result of a lack of strategic fit, or operational underperformance? What is the expected timeline for exit?
Operating Expense Leverage
Adjusted operating expenses grew 21.7% while revenue grew 5.5%. When do you expect the integration costs of RCA and OneOncology to normalize, allowing operating leverage to return?